At a glance
- Originator Baxter Oncology
- Developer Baxter Oncology; National Cancer Institute (USA)
- Class Antineoplastics; Phosphoramide mustards; Small molecules
- Mechanism of Action Alkylating agents; DNA inhibitors; Immunomodulators; Tubulin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Lymphomatous meningitis; Neoplastic meningitis
Most Recent Events
- 03 Dec 2003 Discontinued - Phase-II for Neoplastic meningitis in Germany (Intrathecal)
- 31 May 2000 Phase-II clinical trials for Neoplastic meningitis in Germany (Intrathecal)